GlassScriptPhysician profile
Neil Nimkar
NPI 1811381890
$5,839.85
in general payments reported to CMS, 2019-2025
53 companies · $1,351 in 2025
The $1,351 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $21.55 · 2021: $583 · 2022: $730 · 2023: $995 · 2024: $2,159 · 2025: $1,351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,174 · Long Term Medical Supply Or Device Loan: $1,315 · Education: $16.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,173.84 |
| Long Term Medical Supply Or Device Loan | $1,315.43 |
| Education | $16.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,768.61 | 2021-2025 | |
| Pfizer INC. | $399.42 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $316.39 | 2021-2025 | Reblozyl, Opdivo, Opdualag |
| Genentech USA, INC. | $243.81 | 2021-2025 | Tecentriq, Polivy, Alecensa |
| Janssen Biotech, INC. | $232.35 | 2021-2025 | Tecvayli, Darzalex, Talvey |
| Seagen INC. | $194.65 | 2021-2023 | Tukysa, Adcetris |
| Amgen INC. | $153.28 | 2021-2023 | Lumakras, Nplate, Xgeva |
| Glaxosmithkline, LLC. | $137.74 | 2023-2025 | Zejula, Jemperli, Ojjaara |
| Abbvie INC. | $135.81 | 2021-2025 | |
| Array Biopharma INC | $134.42 | 2021-2025 | Braftovi, Mektovi, Tukysa |
| Merck Sharp & Dohme LLC | $134.18 | 2021-2024 | Keytruda, Lynparza |
| Exelixis INC. | $111.19 | 2022-2025 | Cabometyx |
| Pharmacosmos Therapeutics INC. | $97.81 | 2024-2025 | Monoferric, Cosela |
| Kite Pharma, INC. | $93.73 | 2023-2025 | Yescarta |
| Astellas Pharma US INC | $91.47 | 2022-2025 | Xospata, Vyloy |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $88.57 | 2022-2024 | Reblozyl, Pomalyst |
| Lilly USA, LLC | $87.87 | 2020-2025 | Verzenio, Jaypirca, Retevmo |
| Daiichi Sankyo INC. | $83.74 | 2021-2025 | Enhertu, Datroway |
| Rigel Pharmaceuticals, INC. | $83.33 | 2021-2025 | Rezlidhia, Tavalisse, Gavreto |
| Bayer Healthcare Pharmaceuticals INC. | $82.99 | 2021-2025 | |
| Incyte Corporation | $76.43 | 2022-2025 | Jakafi |
| Janssen Pharmaceuticals, INC | $73.98 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $71.79 | 2023-2025 | Libtayo |
| Emd Serono, INC. | $64.15 | 2021-2025 | |
| Mirati Therapeutics, INC. | $64.04 | 2023-2024 | Krazati |
| Beigene USA, INC. | $62.99 | 2023-2024 | Brukinsa |
| Sirtex Medical INC | $59.89 | 2022-2023 | Sir-Spheres Microspheres |
| Taiho Oncology, INC. | $58.55 | 2024-2025 | |
| Genmab U.S., INC. | $57.46 | 2023-2025 | Tivdak, Epkinly |
| Foundation Medicine, INC. | $46.00 | 2023 | |
| Adaptive Biotechnologies Corporation | $42.94 | 2023-2024 | Clonoseq |
| Astrazeneca Pharmaceuticals LP | $39.74 | 2025 | Lynparza |
| Takeda Pharmaceuticals U.S.A., INC. | $34.54 | 2022 | |
| Stemline Therapeutics INC. | $34.30 | 2025 | Orserdu |
| Eisai INC. | $34.14 | 2021-2024 | |
| Servier Pharmaceuticals LLC | $32.81 | 2024-2025 | |
| Agios Pharmaceuticals, INC. | $31.86 | 2025 | Pyrukynd |
| Cti Biopharma Corp. | $29.08 | 2023 | Vonjo |
| Pharmaessentia USA Corporation | $28.66 | 2022-2023 | Besremi |
| Beone Medicines USA, INC. | $19.21 | 2025 | Brukinsa |
| Tempus Ai, INC | $18.79 | 2024 | |
| Myriad Genetic Laboratories, INC. | $18.71 | 2025 | Myrisk |
| Blueprint Medicines Corporation | $18.03 | 2025 | Ayvakit |
| Deciphera Pharmaceuticals INC. | $17.41 | 2024 | Tgct, Qinlock |
| Azurity Pharmaceuticals, INC. | $17.11 | 2024 | Triptodur |
| Karyopharm Therapeutics INC. | $15.84 | 2023 | Xpovio |
| Verastem, INC. | $15.54 | 2025 | Avmapki Fakzynja Co-Pack |
| Morphosys, US INC. | $14.81 | 2022 | |
| Welch Allyn | $14.55 | 2021 | |
| Tersera Therapeutics LLC | $14.47 | 2023 | Zoladex |
| Immunogen, INC. | $14.09 | 2023 | Elahere |
| Pharmacyclics LLC, An Abbvie Company | $13.35 | 2022 | |
| Baxter Healthcare | $13.23 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neil Nimkar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.